Harvard Pilgrim Health Care Home
  Learn more.
  Sign up for HPHConnect.
Medical Management
For Your Patient
News Center
Network Matters
Newsletter Archives
Newsletter Registration
Office Support
Provider Manual
Medicare Advantage
Research & Teaching
Resources & Links
Print    Text Size

Network Matters
News and Information for the
Harvard Pilgrim Health Care Network

March 2017

Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM) HEDIS Measure

The Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM) HEDIS measure, developed in 2015, calculates the percentage of children ages 1–17 who have had two or more antipsychotic prescriptions filled, at least one metabolic test for blood glucose HbA1c, and at least one test for low-density lipoprotein cholesterol (LCL-C) or total cholesterol each year. Examples of first and second-generation antipsychotic medications included in this measure are chlorpromazine, aripiprazole, clozapine, olanzapine, risperidone, haloperidol, and trifluoperazine.

While antipsychotic medications are effective in treating certain mental illnesses in children, their side effects can lead to or exacerbate other health problems. Children taking antipsychotics are prone to significant weight gain and obesity-related complications such as cardiovascular issues, hypertension, hypercholesterolemia, and insulin-resistant type 2 diabetes. Consequently, it is important that patients on antipsychotic medication have annual metabolic testing.

Twice a year, Harvard Pilgrim sends registries to pediatricians and prescribers, listing their patients ages 1-17 who have had two or more antipsychotic prescriptions filled and are missing a cholesterol and/or blood glucose test in the calendar year. Sending this biannual metabolic monitoring report is a fundamental ongoing initiative of Harvard Pilgrim’s Patient Safety Program, and the next mailing will occur in June. For more information about this Harvard Pilgrim initiative, contact the Clinical Programs Department at 800-287-9793 (option 1).

Email this article to a colleague   

Network Matters Archives

Download printer-friendly version


National Healthcare Decisions Day Emphasizes Advance Care Planning

The Foundation’s Report on Transgender Health Care in Greater Boston


Stelara Coverage and Prior Authorization Criteria Updated

Update: Pudendal Nerve Decompression Coverage

Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM) HEDIS Measure


Appropriate Use of Modifier 91

Harvard Pilgrim Expanding Authorization ID Numbers

Keep Panel Status and Demographic Information Up to Date


Eric H. Schultz,
President and Chief Executive Officer

Robert Farias,
Vice President, Network Services

Annmarie Dadoly,

Joseph O'Riordan,

Kristin Edmonston,
Production Coordinator